MAPT and Alzheimer disease: In a first study performed with a novel ECLIA technique, plasma p-tau concentrations not only could discriminate AD and frontotemporal lobar degeneration (FTLD) participants with good accuracy, but they also identified amyloid-PET positive participants among elderly and MCI, and they predicted the rate of cognitive decline in AD and MCI over a 2-year follow-up (Table 3) [91].